Pillar 1 - FTO (new thread), page-1796

One of my concerns with RAC _{(it's a very short list)}, has been the lack of acknowledgement of Zantrene^® as the Best-In-Class inhibitor of FTO by the wider scientific community. If we have the BIC molecule then why, since June 2020, has Zantrene^® only been acknowledged by the Chicago Paper?

I've raised this before and Dr T gave his thoughts:


So I've been content to believe that all these groups are just ignoring Zantrene for now.
I just wish there was another independent study, NOT looking for FTO inhibitors that could reinforce this theory a bit more.......oh hello...

A French research team has been looking into what role the m6A methylation pathway has in insulin secretion in Type 2 Diabetes. They gave glucose to Pancreatic Islets (cells harvested from persons with T2D) and observed that among other things, FTO became increased. So they wanted to see how insulin secretion would be impacted by FTO inhibition...



This team wasn't looking for FTO inhibitors themselves, and so they were happy to use the best, Zantrene^®. For me at least this confirms the theory of why we aren't seeing Zantrene in more studies. I'm happy to put this one to bed and make my very short list of concerns even shorter.

Now, I don't want to gloss over the fact that we also now have THREE independent verifications of Zantrene as an FTO inhibitor, AND this paper goes on to detail that Zantrene improved insulin secretion...


Three big positives from the one study, not bad. It's still very early days regarding T2D, and not something I expect RAC to pursue, but this is just another attractive lead Big Pharma can investigate once the dust from the bidding war has settled.

Enjoy your weekends everybody.
S.E